Timothy F. Burns, MD, PhD, on the Current Landscape of KRAS G12C Inhibitors in the Treatment of NSCLC

Posted: Tuesday, September 3, 2024

Timothy F. Burns, MD, PhD, of the University of Pittsburgh, Hillman Cancer Center Research Pavilion, discusses the findings from the phase I/ll study LOXO-RAS-20001 and how KRAS G12C inhibitors are positioned in the first-line setting of NSCLC. This clinical trial reported early results with the combination of the PD-1 inhibitor pembrolizumab and the second-generation KRAS G12C inhibitor olomorasib.

---